Monitoring progress towards the first UNAIDS 90-90-90 target in key populations living with HIV in Norway.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
26 Jun 2020
Historique:
received: 14 02 2020
accepted: 18 06 2020
entrez: 28 6 2020
pubmed: 28 6 2020
medline: 8 7 2020
Statut: epublish

Résumé

In line with the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, Norway aims for at least 90% of people living with HIV (PLHIV) to know their HIV-status. We produced current estimates of the number of PLHIV and undiagnosed population in Norway, overall and for six key subpopulations: Norwegian-born men who have sex with men (MSM), migrant MSM, Norwegian-born heterosexuals, migrant Sub-Saharan Africa (SSA)-born heterosexuals, migrant non-SSA-born heterosexuals and people who inject drugs. We used the European Centre for Disease Prevention and Control (ECDC) HIV Modelling Tool on Norwegian HIV surveillance data through 2018 to estimate incidence, time from infection to diagnosis, PLHIV, and the number and proportion undiagnosed. As surveillance data on CD4 count at diagnosis were not collected in Norway, we ran two models; using default model CD4 assumptions, or a proxy for CD4 distribution based on Danish national surveillance data. We also generated alternative overall PLHIV estimates using the Spectrum AIDS Impact Model, to compare with those obtained from the ECDC tool. Estimates of the overall number of PLHIV in 2018 using different modelling approaches aligned at approximately 5000. In both ECDC models, the overall number undiagnosed decreased continuously from 2008. The proportion undiagnosed in 2018 was lower using default model CD4 assumptions (7.1% [95%CI: 5.3-8.9%]), than the Danish CD4 proxy (10.2% [8.3-12.1%]). This difference was driven by results for heterosexual migrants. Estimates for Norwegian-born MSM, migrant MSM and Norwegian-born heterosexuals were similar in both models. In these three subpopulations, incidence in 2018 was < 30 new infections, and the number undiagnosed had decreased in recent years. Norwegian-born MSM had the lowest estimated number of undiagnosed infections (45 [30-75], using default CD4 assumptions) and undiagnosed fraction (3.6% [2.4-5.7%], using default CD4 assumptions) in 2018. Results allow cautious confidence in concluding that Norway has achieved the first UNAIDS 90-90-90 target, and clearly highlight the success of prevention strategies among MSM. Estimates for subpopulations strongly influenced by migration remain less clear, and future modelling should appropriately account for all-cause mortality and out-migration, and adjust for time of in-migration.

Sections du résumé

BACKGROUND BACKGROUND
In line with the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, Norway aims for at least 90% of people living with HIV (PLHIV) to know their HIV-status. We produced current estimates of the number of PLHIV and undiagnosed population in Norway, overall and for six key subpopulations: Norwegian-born men who have sex with men (MSM), migrant MSM, Norwegian-born heterosexuals, migrant Sub-Saharan Africa (SSA)-born heterosexuals, migrant non-SSA-born heterosexuals and people who inject drugs.
METHODS METHODS
We used the European Centre for Disease Prevention and Control (ECDC) HIV Modelling Tool on Norwegian HIV surveillance data through 2018 to estimate incidence, time from infection to diagnosis, PLHIV, and the number and proportion undiagnosed. As surveillance data on CD4 count at diagnosis were not collected in Norway, we ran two models; using default model CD4 assumptions, or a proxy for CD4 distribution based on Danish national surveillance data. We also generated alternative overall PLHIV estimates using the Spectrum AIDS Impact Model, to compare with those obtained from the ECDC tool.
RESULTS RESULTS
Estimates of the overall number of PLHIV in 2018 using different modelling approaches aligned at approximately 5000. In both ECDC models, the overall number undiagnosed decreased continuously from 2008. The proportion undiagnosed in 2018 was lower using default model CD4 assumptions (7.1% [95%CI: 5.3-8.9%]), than the Danish CD4 proxy (10.2% [8.3-12.1%]). This difference was driven by results for heterosexual migrants. Estimates for Norwegian-born MSM, migrant MSM and Norwegian-born heterosexuals were similar in both models. In these three subpopulations, incidence in 2018 was < 30 new infections, and the number undiagnosed had decreased in recent years. Norwegian-born MSM had the lowest estimated number of undiagnosed infections (45 [30-75], using default CD4 assumptions) and undiagnosed fraction (3.6% [2.4-5.7%], using default CD4 assumptions) in 2018.
CONCLUSIONS CONCLUSIONS
Results allow cautious confidence in concluding that Norway has achieved the first UNAIDS 90-90-90 target, and clearly highlight the success of prevention strategies among MSM. Estimates for subpopulations strongly influenced by migration remain less clear, and future modelling should appropriately account for all-cause mortality and out-migration, and adjust for time of in-migration.

Identifiants

pubmed: 32590964
doi: 10.1186/s12879-020-05178-1
pii: 10.1186/s12879-020-05178-1
pmc: PMC7318482
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

451

Références

AIDS. 2017 Apr;31 Suppl 1:S23-S30
pubmed: 28296797
AIDS. 2019 Dec 15;33 Suppl 3:S227-S234
pubmed: 31805028
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Lancet. 2019 Jun 15;393(10189):2428-2438
pubmed: 31056293
Clin Infect Dis. 2017 Jun 15;64(12):1644-1656
pubmed: 28369283
PLoS One. 2018 May 24;13(5):e0197990
pubmed: 29795698
Euro Surveill. 2016 Dec 1;21(48):
pubmed: 27934585
Lancet HIV. 2019 Dec;6(12):e831-e859
pubmed: 31439534
Sex Transm Dis. 2014 Mar;41(3):209-14
pubmed: 24521728
Int J Epidemiol. 2019 Dec 1;48(6):1795-1803
pubmed: 31074780
Epidemics. 2010 Jun;2(2):66-79
pubmed: 21352777
Infect Genet Evol. 2018 Jul;61:36-44
pubmed: 29522828
Epidemiology. 2015 Sep;26(5):653-60
pubmed: 26214334
AIDS. 2019 Dec 15;33 Suppl 3:S271-S281
pubmed: 31800404
AIDS. 2019 Dec 15;33 Suppl 3:S245-S253
pubmed: 31385865
Euro Surveill. 2019 Apr;24(14):
pubmed: 30968824
AIDS. 2017 Apr 24;31(7):953-963
pubmed: 28121710
J Epidemiol Biostat. 2000;5(4):233-43
pubmed: 11055273
AIDS. 2018 Nov 13;32(17):2573-2581
pubmed: 30096075
HIV Med. 2017 Oct;18(9):677-684
pubmed: 28444865
J Int AIDS Soc. 2019 Aug;22(8):e25371
pubmed: 31424626
BMJ Open. 2017 Oct 6;7(10):e017598
pubmed: 28988180
Fed Pract. 2016 Apr;33(Suppl 3):24S-30S
pubmed: 30766212
Stat Med. 2017 Jan 30;36(2):334-344
pubmed: 27672002
J Int AIDS Soc. 2018 Mar;21(3):e25100
pubmed: 29603879
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
Top Antivir Med. 2018 Apr;25(4):138-142
pubmed: 29689539
Curr Opin HIV AIDS. 2016 Sep;11(5):492-500
pubmed: 27254748
Eur J Public Health. 2003 Sep;13(3):252-8
pubmed: 14533729
Epidemiology. 2016 Mar;27(2):247-56
pubmed: 26605814
PLoS One. 2012;7(9):e44819
pubmed: 23024766

Auteurs

Robert Whittaker (R)

Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway. robert.whittaker@fhi.no.
European Program for Intervention Epidemiology Training, European Centre for Disease Prevention and Control, Stockholm, Sweden. robert.whittaker@fhi.no.

Kelsey K Case (KK)

Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Øivind Nilsen (Ø)

Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway.

Hans Blystad (H)

Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway.

Susan Cowan (S)

Statens Serum Institut, Copenhagen, Denmark.

Hilde Kløvstad (H)

Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway.

Ard van Sighem (A)

Stichting HIV Monitoring, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH